30
Participants
Start Date
April 30, 2008
Primary Completion Date
February 28, 2017
Study Completion Date
February 28, 2017
rituximab, cyclophosphamide, etoposide, prednisone, vorinostat and QOL questionnaire, peg-filgrastim or filgrastim
Patients will be treated with 6 cycles of rituximab, cyclophosphamide, etoposide, prednisone and vorinostat every 4 weeks. Quality of life determinations will be obtained at the beginning of each cycle of chemotherapy and at each visit during the first year of followup.
Memorial Sloan Kettering Cancer Center, New York
Memorial Sloan Kettering Cancer Center @ Phelps, Sleepy Hollow
Memorial Sloan Kettering Cancer Center @ Suffolk, Commack
Memorial Sloan Kettering Cancer Center @ BaskingRidge, Basking Ridge
Weill Cornell Medical Center, New York
Collaborators (1)
Merck Sharp & Dohme LLC
INDUSTRY
Northwestern University
OTHER
Endeavor Health
OTHER
Weill Medical College of Cornell University
OTHER
Memorial Sloan Kettering Cancer Center
OTHER